Cardiovascular Abnormalities: Clinical Trials

130 trials for Cardiovascular Abnormalities, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

74 completed, 17 terminated, 11 recruiting, 10 unknown. 130 Phase 1, 47 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1130Completed 74, Terminated 17, Recruiting 11, Unknown 10, Active not recruiting 6, Not yet recruiting 6, Withdrawn 5, Suspended 1
Phase 247Completed 24, Recruiting 6, Unknown 6, Active not recruiting 4, Terminated 4, Not yet recruiting 1, Suspended 1, Withdrawn 1

Follow Cardiovascular Abnormalities: new trials by email Literature Review of Cardiovascular Abnormalities trials Research Report on Cardiovascular Abnormalities

Trials (filtered) newest first · largest first

All 130 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congenital Heart Disease Undergoing Surgical Repair
End-expiratory lung volume optimization maneuver with PEEP titration, Standard Care (in control arm) - Congenital Heart Disease, Cardiopulmonary Bypass
Phase 1 / Phase 2Not yet recruitingCharite University, Berlin, Germany802027-01-012026-10-15
Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
TX002100 - Hereditary Hemorrhagic Telangiectasia (HHT)
Phase 1Not yet recruitingTectonic Operating Company, Inc.202026-12-312026-10-15
Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration
NRL-1049, Placebo - Cerebral Cavernous Malformation
Phase 1Not yet recruitingNeurelis, Inc.402026-11-112026-10-30
Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids
2 mL SunButyrate-TG, Placebo, 4 mL SunButyrate-TG - Congenital Heart Disease (CHD)
Phase 1 / Phase 2RecruitingUniversity of Nebraska1052026-11-012026-10-30
Topical TOR-582 Treatment of Epistaxis in HHT
Topical sirolimus ointment - Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Phase 1Not yet recruitingColumbia University272026-10-012026-08-21
ATR 1072 in Participants With PRKAG2 Syndrome
ATR 1072 - Cardiac Glycogenosis, Cardiomyopathy
Phase 1 / Phase 2RecruitingAtrium Therapeutics372026-09-142026-09-18
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
ATV-1601, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Phase 1 / Phase 2RecruitingAtavistik Bio, Inc1002026-07-272026-10-29
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
DIAG723, Placebo - Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
Phase 1 / Phase 2RecruitingDiagonal Therapeutics, Inc.932026-06-042026-09-08
A Multiple Baseline Feasibility Trial of Social Management Training for People With Sex Chromosome Aneuploidies
Social Management Training - Sex Chromosome Disorders
Phase 1RecruitingUniversity of Oslo302026-06-012026-07-22
A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
TER-1754, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT)
Phase 1WithdrawnTerremoto Biosciences Inc.2025-12-152026-04-13
Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children
End-expiratory lung volume optimization maneuver with PEEP titration, Standard Care (in control arm) - Congenital Heart Disease, Cardiopulmonary Bypass
Phase 1 / Phase 2RecruitingCharite University, Berlin, Germany802025-12-052026-10-15
In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment
Single in situ intra-arterial injection of bevacizumab - Brain Arteriovenous Malformations
Phase 1Not yet recruitingAssistance Publique - Hôpitaux de Paris202025-10-012025-07-20
Propranolol Treatment for Postoperative Chylothorax
Propranolol Hydrochloride, Placebo - Postoperative Chylothorax, Congenital Heart Disease
Phase 1 / Phase 2SuspendedJune Wu502025-09-092026-05-15
Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)
Ventrix Bio Extracellular Matrix - Hypoplastic Left Heart Syndrome
Phase 1Not yet recruitingEmory University122025-08-012025-03-10
Trametinib Treatment for Complicated Vascular Anomalies
Trametinib tablet - Vascular Anomalies
Phase 1 / Phase 2Active not recruitingWest China Hospital202025-07-072025-07-22
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
ALN-6400, Placebo - Hereditary Hemorrhagic Telangiectasia
Phase 1 / Phase 2Active not recruitingAlnylam Pharmaceuticals892024-11-072026-10-15
Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
RCT1100 - Primary Ciliary Dyskinesia (PCD)
Phase 1CompletedReCode Therapeutics142024-10-222026-04-30
PK/PD of Digoxin in Infants With SVHD
PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease - Single-ventricle, Infant Conditions
Phase 1 / Phase 2CompletedDuke University242024-10-102026-08-14
A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD
RCT1100 - Primary Ciliary Dyskinesia
Phase 1CompletedReCode Therapeutics72024-09-202025-10-08
IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy
IC14 - Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Left Ventricular Cardiomyopathy
Phase 1 / Phase 2CompletedImplicit Bioscience12024-03-292026-04-22

Showing 20 of 130. Sign in to see all of them.

Narrower conditions

Heart Defects, Congenital (32)  ·  Hypoplastic Left Heart Syndrome (16)  ·  Telangiectasia, Hereditary Hemorrhagic (15)  ·  Long QT Syndrome (13)  ·  Noonan Syndrome (11)  ·  Carcinoma, Non-Small-Cell Lung (8)  ·  Vascular Malformations (8)  ·  Arteriovenous Malformations (7)  ·  Epistaxis (7)  ·  Colorectal Neoplasms (6)  ·  Squamous Cell Carcinoma of Head and Neck (6)  ·  DiGeorge Syndrome (5)  ·  Tetralogy of Fallot (5)  ·  Univentricular Heart (5)  ·  Arrhythmogenic Right Ventricular Dysplasia (4)

Broader conditions

Congenital Abnormalities (130)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (130)  ·  Cardiovascular Diseases (127)  ·  Heart Diseases (92)  ·  Heart Defects, Congenital (66)  ·  Pathological Conditions, Signs and Symptoms (39)  ·  Pathologic Processes (35)  ·  Vascular Diseases (28)  ·  Hemic and Lymphatic Diseases (26)  ·  Respiratory Tract Diseases (21)  ·  Vascular Malformations (21)  ·  Hematologic Diseases (17)  ·  Hemorrhagic Disorders (17)  ·  Hemostatic Disorders (17)

Interventions

Acetaminophen (4)  ·  Dexmedetomidine (4)  ·  Moxifloxacin (4)  ·  eleclazine (4)  ·  Saline Solution (3)  ·  Capsules (2)  ·  Dexrazoxane (2)  ·  Doxycycline (2)  ·  Ibuprofen (2)  ·  Injections (2)  ·  Propranolol (2)  ·  Sildenafil Citrate (2)  ·  Sodium Chloride (2)  ·  Standard of Care (2)  ·  Sugars (2)

Sponsors

Gilead Sciences (4)  ·  Sumitomo Pharma Switzerland GmbH (4)  ·  Boston Children's Hospital (3)  ·  Jacobio Pharmaceuticals Co., Ltd. (3)  ·  ReCode Therapeutics (3)  ·  The Hospital for Sick Children (3)  ·  Timothy J Nelson, MD, PhD (3)  ·  University of California, San Francisco (3)  ·  Albireo (2)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Athena Zuppa (2)  ·  Carelon Research (2)  ·  Charite University, Berlin, Germany (2)  ·  Children's Hospital of Philadelphia (2)  ·  Duke University (2)

Countries

United States (88)  ·  Canada (8)  ·  China (8)  ·  Australia (5)  ·  France (5)  ·  Germany (5)  ·  Spain (5)  ·  New Zealand (3)  ·  United Kingdom (3)  ·  Finland (2)  ·  Italy (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Romania (2)  ·  Singapore (2)

Top investigators

John Matthews, MBBS, MCRP, PhD (3)  ·  M. Louise Markert, MD, PhD (3)  ·  Muhammad Y Qureshi, MBBS (3)  ·  Timothy J Nelson, M.D., Ph.D. (3)  ·  Outi Aikio, MD, PhD (2)  ·  Revolution Medicines, Inc. (2)  ·  William Mahle, MD (2)  ·  Yuankai Shi, MD (2)  ·  Adelina Pellicer, PhD (1)  ·  Aditya K Kaza (1)  ·  Alfred T Lane, MD (1)  ·  Allan Doctor, MD (1)  ·  Ana Paula CP Carlotti, 1 (1)

Results publications

PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 15100156, PMID 17284531, PMID 23607606, PMID 15100681, PMID 17662768, PMID 18155964, PMID 18212521, PMID 18333898, PMID 19217726, PMID 20978268, PMID 22590644, PMID 23102686, PMID 23172172, PMID 23228403, PMID 23771484, PMID 23823195, PMID 24201857, PMID 24252784, PMID 24481211, PMID 24656411, PMID 24666686, PMID 25403163, PMID 26232942, PMID 26951240, PMID 28750642, PMID 28800628, PMID 29367212, PMID 30501611, PMID 30542204, PMID 31623840, PMID 32083653, PMID 32894644, PMID 33400845, PMID 33733338, PMID 34217109, PMID 34265312, PMID 34479739, PMID 35394149, PMID 35690720, PMID 37120522, PMID 37264205, PMID 37527726, PMID 37979797, PMID 38629477, PMID 39510938

NIH funding

K12HD043494 (4), R01AI047040 (4), R01AI054843 (4), 2014 (2), 2023 (2), R56AI047040 (2), 2016 (1), 2025 (1), R01HD106588 (1), R01HL073317 (1), R01HL149139 (1), R01HL155597 (1), R21HD055501 (1), R56HL128813 (1), U10HD045986 (1)